MedTrace Logo

The Inperia Advance Post-Market Retrospective Study

NCT05622084 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-11-18

No results posted yet for this study

Summary

The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis. The aim of this post-market retrospective study protocl P32203 is to collect clinical data of patients treated with Inperia Advance for the treatment of infra-popliteal artery stenosis in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the device at least 12 months prior to the study start.

Conditions

  • Peripheral Arterial Disease

Interventions

DEVICE

Inperia Advance

Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device

Sponsors & Collaborators

  • Meditrial Europe Ltd.

    collaborator INDUSTRY

  • CID S.p.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-06-30
Completion
2023-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622084 on ClinicalTrials.gov